



Contribution ID: 86

Type: Oral presentations

Gallium-68 –a candidate for use in clinical routine

Wednesday, 3 February 2010 11:35 (25 minutes)

The $^{68}\text{Ge}/^{68}\text{Ga}$ radionuclide generator (^{68}Ge , $T_{1/2} = 270.95$ d) is an excellent cyclotron-independent source for the positron emitter ^{68}Ga which is successfully used in clinical PET. Nevertheless there remain open problems in the routine use related to the applicability of the technique in clinical environment and legal aspects. An effective application of the generator produced ^{68}Ga can be limited by poor chemical and pharmaceutical quality of the generator eluate. Thus traces of metals, as a consequence of the use of metal oxide based matrixes; rather large volume and high acidity lead to suboptimal conditions of the radiolabelling reaction and can decrease the reproducibility in the routine preparation of ^{68}Ga -radiopharmaceuticals. In order to extend the shelf-life of the generator systems, high initial activities of the ^{68}Ge are used. A long-term utilization of the generator systems in non-gmp environment can cause, however, decreasing of pharmaceutical quality and conflict with legal aspects of in-house radiopharmaceutical production. Finally, users face the problem of the generator utilization, since long-lived ^{68}Ge can not be declared as decay waste.

In this context we propose a novel "metal free" $^{68}\text{Ge}/^{68}\text{Ga}$ radionuclide generator system dedicated for production of high quality gmp grade ^{68}Ga preparations. The concept includes an effective ^{68}Ge management and improved logistic for the routine utilization of the radionuclide generator system in clinical environment.

Please submit a short bio (max 1500 characters)

Dr.-Ing. Mark Harfensteller studied Mechanical Engineering at the Technische Universitaet Muenchen. He specialized in the field of production technology where he joined Prof. Zaeh and Prof. Reinhart at the institute of machine tools and industrial management (iwb) from 2002 to 2006. Besides production development in mechatronic and chemical engineering he focused in the development of production technology of the alpha-emitter Actinium-225 by the proton irradiation of Radium-226.

Mark accompanied the successful Ac-225 project until 2008 where he joined ITG isotope technologies Garching as head of production.

Last Name

Harfensteller

Institution

Isotope Technologies Garching

First Name(s)

Mark

Telephone

+49 89 28913923

Address

Lichtenbergstr. 1

E-mail address

mark.harfensteller@itg-garching

Author: Dr HARFENSTELLER, Mark (ITG Isotope Technologies Garching, Germany)

Co-authors: Prof. TÜRLER, Andreas (Paul Scherrer Institut, Villigen); Dr MORENO, Josue (ITG Isotope Technologies Garching, Germany); Dr ZHERNOSEKOV, Konstantin (Paul Scherrer Institut, Villigen); BUCK, Oliver (ITM Isotope Technologies Munich, Garching); LEIB, Oliver (ITG Isotope Technologies Garching, Germany); Dr HENKELMANN, Richard (ITG Isotope Technologies Garching, Germany); Dr NIKULA, Tuomo (ITM Isotope Technologies Munich, Garching)

Presenter: Dr HARFENSTELLER, Mark (ITG Isotope Technologies Garching, Germany)

Session Classification: Session 2: Radioisotopes in diagnostics and therapy

Track Classification: Radioisotopes in diagnostics and therapy